New research offers CRO market snapshot

By Kirsty Barnes

- Last updated on GMT

Related tags: Cent, Clinical trial

New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.

Currently, the total spend on CROs is pegged at $15bn (€10.3bn) and a growth rate of 15 per cent is expected over the next seven years, Frost & Sullivan Research Analyst, Barath Shankar told in an interview. Within the sector, Shankar said there has been a lot of Phase IV activity of late and he expects this to be the fastest growing clinical subsection. "We are experiencing and expect to continue seeing a compound annual growth rate (CAGR) of 12-13 per cent for the early stage areas and a 15 per cent growth in the late phases over the next seven years,"​ he said. As far a breakdown on spend for each phase of clinical development, Phase III unsurprisingly captures the largest proportion, with 24 per cent. Preclinical, Phase II and Phase IV are equally split at 20 per cent each, while the least amount (15 per cent) is spent on Phase I. Presently, two thirds of CRO spending originates from big pharma, but biotechs are now driving a lot of this industry's growth, said Shankar. Regionally, the US remains the dominant clinical trial destination, holding 60 per cent of the volume. Europe is a long way behind, with only 14 per cent of study volume, while the remaining 16 per cent is scattered around the rest of the world. Over the next six years or so the US' share is expected to erode to 52 per cent, with Europe picking up 6 per cent and the remainder going to the rest of the world. "During this time, all the emerging markets are only going to grow in low single digit numbers [2-3 per cent],"​ said Shankar. Further details of the research can be found in the report, titled: "Global CRO Spending Trends".

Related news

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more